Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000054.xml
Pharmacopsychiatry 2018; 51(03): 106-107
DOI: 10.1055/s-0043-109241
DOI: 10.1055/s-0043-109241
Letter to the Editor
Author’s Reply to the Letter to the Editor by Fountoulakis
Crocus sativus L. versus CitalopramFurther Information
Publication History
received 25 February 2017
revised 16 April 2017
accepted 18 April 2017
Publication Date:
08 May 2017 (online)
-
References
- 1 Ghajar A, Neishabouri S, Velayati N. et al. Crocus sativus L. versus Citalopram in the Treatment of Major Depressive Disorder with Anxious Distress: A Double-Blind, Controlled Clinical Trial. Pharmacopsychiatry 2016;
- 2 Sibbald B, Roland M. Understanding controlled trials. Why are randomised controlled trials important? BMJ. British Medical Journal 1998; 316: 201
- 3 Zimmerman M, Martinez JH, Young D. et al. Severity classification on the Hamilton depression rating scale. Journal of affective disorders 2013; 150: 384-388
- 4 Rush A, First M, Blackar D. Handbook of Psychiatric Measures. American Psychiatric Publishing. Inc; Washington: 2008
- 5 Geromichalos GD, Lamari FN, Papandreou MA. et al. Saffron as a source of novel acetylcholinesterase inhibitors: Molecular docking and in vitro enzymatic studies. Journal of agricultural and food chemistry 2012; 60: 6131-6138
- 6 Lopresti AL, Drummond PD. Efficacy of curcumin, and a saffron/curcumin combination for the treatment of major depression: A randomised, double-blind, placebo-controlled study. Journal of affective disorders 2017; 207: 188-196
- 7 Ravindran AV, Balneaves LG, Faulkner G. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 5. complementary and alternative medicine treatments. The Canadian Journal of Psychiatry 2016; 61: 576-587